tailieuchung - Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Đang chuẩn bị liên kết để tải về tài liệu:
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Bảo Thái 55 9 pdf

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ Tải xuống

Crizotinib can target against mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK), which has been considered as a multi-targeted tyrosine kinase inhibitor (TKI). | Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Đang chuẩn bị liên kết để tải về tài liệu:
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Crizotinib can target against mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK), which has been considered as a multi-targeted tyrosine kinase inhibitor (TKI). | Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: A case report

The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: A meta-analysis of clinical trials

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

A retrospective study of alectinib versus ceritinib in patients with advanced non– small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Alteration in the sensitivity to crizotinib by Na+ /H+ exchanger regulatory factor 1 is dependent to its subcellular localization in ALK-positive lung cancers

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: A case report and literature review

Post-crizotinib management of effective ceritinib therapy in a patient with ALKpositive non-small cell lung cancer

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma

Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: A case report

Đang chuẩn bị liên kết để tải về tài liệu: Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

Crizotinib can target against mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK), which has been considered as a multi-targeted tyrosine kinase inhibitor (TKI). | Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: A case report

The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: A meta-analysis of clinical trials

Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer

A retrospective study of alectinib versus ceritinib in patients with advanced non– small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

Alteration in the sensitivity to crizotinib by Na+ /H+ exchanger regulatory factor 1 is dependent to its subcellular localization in ALK-positive lung cancers

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: A case report and literature review

Post-crizotinib management of effective ceritinib therapy in a patient with ALKpositive non-small cell lung cancer

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma

Fatal interstitial lung disease associated with Crizotinib pathologically confirmed by percutaneous lung biopsy in a patient with ROS1-rearranged advanced non-small-cell lung cancer: A case report

Đang chuẩn bị liên kết để tải về tài liệu:
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression